Publications by authors named "R C Brundage"

The current demand for pharmacometricians outmatches the supply provided by academic institutions and considerable investments are made to develop the competencies of these scientists on-the-job. Even with the observed increase in academic programs related to pharmacometrics, this need is unlikely to change in the foreseeable future, as the demand and scope of pharmacometrics applications keep expanding. Further, the field of pharmacometrics is changing.

View Article and Find Full Text PDF
Article Synopsis
  • * Hmong participants (n=34) were given increasing doses of allopurinol, and a pharmacokinetic-pharmacodynamic analysis was performed to simulate personalized dosing based on their genetic makeup.
  • * The findings suggest that specific genotypes, alongside factors like body mass and kidney function, significantly affect oxypurinol clearance, helping tailor dosages for effective treatment while indicating that some genotypes may need alternative medications.
View Article and Find Full Text PDF

In a nonlinear mixed-effects modeling (NLMEM) approach of pharmacokinetic (PK) and pharmacodynamic (PD) data, two levels of random effects are generally modeled: between-subject variability (BSV) and residual unexplained variability (RUV). The goal of this simulation-estimation study was to investigate the extent to which PK and RUV model misspecification, errors in recording dosing and sampling times, and variability in drug content uniformity contribute to the estimated magnitude of RUV and PK parameter bias. A two-compartment model with first-order absorption and linear elimination was simulated as a true model.

View Article and Find Full Text PDF
Article Synopsis
  • Buprenorphine is commonly prescribed for opioid use disorder (OUD), but limited pharmacokinetic studies exist for diverse populations, prompting this pilot study to investigate its dynamics in patients with and without HIV.
  • The study measured plasma levels in 54 patients to assess the drug's clearance and distribution using a model that accounted for factors like weight and HIV status.
  • Results revealed that buprenorphine clearance and volume of distribution were significantly higher in HIV-positive patients, suggesting that their bodies process the medication differently, potentially impacting its effectiveness and bioavailability.
View Article and Find Full Text PDF